contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


clinical-guideline-for-nevisense-published-in-germany

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

SciBase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.

The stock is surging for some reason. I don’t see any news, at least.

Now, apparently, a solution is being sought in connection with a share issue for this difficult capital structure due to TO2 warrants. Warrants are being converted into shares here, so that two warrants are exchanged for one share                    Inderes              The Board of Directors in SciBase resolves on an offer to repurchase...    The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") has today resolved to make a repurchase offer for all 498,534,835 outstanding warrants of series TO 2 in the ...                             That TO2 warrant structure made the company’s valuation exceptionally complex during our company coverage, so, fundamentally, evaluating the company as an investment will become easier with this

Where can I buy those warrants? They sound like a very interesting investment if the maturity period is that long.

Thanks for the insights. Can more experienced investors estimate how common it is for the option exercise period to be set so far out, all the way to spring 2029? It feels like a very long timeframe. This is indeed a big hindrance to the share price increase, especially since such a huge number of options are redeemable. Or how do the rest of you see it?

Interesting company, and with the increasing prevalence of melanoma, the market should grow. I personally held a small position in this, but those warrants seem to prevent a larger price increase. In addition, revenue growth has been so slow that a new share issue (and more warrants) might be on the horizon again by the end of the year. The number of employees has now slightly increased, apparently the US sales organization has been strengthened?

Unfortunately, the coverage ended a while ago, so we don’t have fresh comments available. If one considers the share price formation, this point about the termination of coverage is very essential to keep in mind:  We highlight that the high number of TO2 warrants (strike price SEK 0.42) has a significant impact on the valuation of the company and investors should evaluate the warrants’ claim on the company’s equity value when assessing the valuation of the stock.

Coverage agreement terminated and coverage ended in December 2024:                  Inderes              SciBase: We are discontinuing coverage - Inderes    We are discontinuing our coverage of SciBase as the company has terminated the research service agreement. Consequently, we will no longer give the stock a target price (prev. 0.45 SEK) or recommendation (prev. Reduce).

Scibase Holding

The article is titled "EIS: Atypien von Hautveränderungen präzise messen" or in English "EIS: Precise measurement of atypia of skin lesions". It outlines a recommended protocol for the use of...

The article is titled "EIS: Atypien von Hautveränderungen präzise messen" or in English "EIS: Precise measurement of atypia of skin lesions". It outlines a recommended protocol for the use of Nevisense in the evaluation of lesions where there is suspicion of malignant melanoma and the recommended action based on the result of the Nevisense measurement. The article also includes a reimbursement recommendation from Onkoderm.The article describing the guideline is now available in online form at the Der Deutsche Dermatologe website (<a href="https://www.springermedizin.de/der-deutsche-dermatologe-11-2018/16277500">https://www.springermedizin.de/der-deutsche-dermatologe-11-2018/16277500</a>) and will be distributed in print to German Dermatologists and associated professionals."Guidelines are an essential step along the way to becoming standard of care, and we are very happy the pre-eminent German organization within skin cancer, OnkoDerm, has chosen to support this guideline and reimbursement approach. We believe that this, combined with our improved system Nevisense 3.0, will drive both our user base and existing customers' usage in German speaking countries. ", says Simon Grant, CEO of SciBase.For more information, please contact: Simon Grant, CEO SciBase Tel: +46 72 887 43 99 Email: <virtloc>simon.grant@scibase.com</virtloc> This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.30 CET on November 19, 2018.About SciBase and NevisenseSciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB"). Avanza is the certified advisor. Further information is available on www.scibase.com.